ReviewMaterials today. Bio2025
Magnetic hyperthermia in oncology: Nanomaterials-driven combinatorial strategies for synergistic therapeutic gains.
Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Design and Physicochemical Characterization of a Multifunctional Maisine-Based Microemulsion Incorporating Doxorubicin@Mn-Doped Magnetite Nanoparticles for MRI, Hyperthermia, and Drug Delivery.Nanomaterials (Basel, Switzerland) · 2026Article
- Recent Advances in Ferrite-Based Materials for Biomedical Applications: A Comprehensive Review.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Advances in improving cancer immunotherapy with nanotechnology: from smart nanoparticles to synergistic combination strategies.Molecular cancer · 2026Review
- Magnetic Fields in Cancer Therapy: Mechanistic Insights, Signaling Pathways, and Evidence from Clinical and In Vitro Studies.Pharmaceutics · 2026Review
- Nanomaterials: An innovative integrative paradigm for hepatocellular carcinoma adjuvant treatment.Asian journal of pharmaceutical sciences · 2026Review
- Nanostructured lipid carriers as co-delivery systems for cancer therapy: Prospects and challenges.International journal of pharmaceutics: X · 2026Review
- Nanoparticle Strategies for Bone Metastasis Immunotherapy: Targeting, Immune Reprogramming and Combination Therapy.Pharmaceutics · 2026Review
- Spatiotemporal cancer controlNanomedicine (London, England) · 2026Review
- Fabrication and characterization of α‑FeDiscover nano · 2026Article
- Au clusterzymes encapsulated in nanogel activated by alternating magnetic field to promote white fat browning and combat obesity.Journal of nanobiotechnology · 2026Article
- Magnetic Field-Guided Magnetic Nanoparticles as Neurotherapeutics for Neurological Disorders and Glioblastoma.Life (Basel, Switzerland) · 2026Review
- Recent advances in cancer nanomedicine: From smart targeting to personalized therapeutics - pioneering a new era in precision oncology.Materials today. Bio · 2026Review
- Article
- Orchestrating Chemo-Ferroptosis via Nonthermal Magnetocatalysis: A Cascade Amplification Paradigm for Breast Cancer Therapy.Biomaterials research · 2026Article
- Magnetic hyperthermia as an intracellular immunomodulatory technology: From heat transduction to tumor immune reprogramming.Theranostics · 2026Review
- Therapeutic Metal Ions: Engineering Biomaterials for Multimodal Disease Treatment.International journal of nanomedicine · 2026Review
- Magnetic Hydrogels as a Treatment for Oncological Pathologies.Journal of functional biomaterials · 2025Review
- Nanoparticle-mediated magnetic hyperthermia in the treatment of neurological disorders.Nanomedicine (London, England) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer cures remain limited with conventional treatments due to tumor microenvironment (TME)-driven resilience and systemic toxicity. Magnetic hyperthermia therapy (MHT), which utilizes magnetic nanoparticles (MNPs) to convert alternating magnetic field (AMF) energy into localized heat, has emerged as a minimally invasive and spatially precise strategy for tumor ablation. This review critically examines the evolution of MHT from its historical roots to cutting-edge combinatorial strategies. The unique advantages of MHT over other hyperthermia modalities are firstly analyzed, highlighting its ability to synergize with the hypoxic and acidic TME for enhanced tumor cell susceptibility. In addition, the pathophysiological mechanisms of cell death induced by MHT were summarized in detail. Next, MHT-optimized nanomaterials are systematically classified based on their heating efficiency, biodistribution, and functionalization strategies for tumor targeting. A key focus lies in elucidating the multimodal therapeutic synergy between MHT and established oncology treatments:(photothermal therapy [PTT], radiotherapy, chemotherapy, immunotherapy) and analyzed the clinical translational bottlenecks of each combination. Finally, the review delineates the translational roadmap of MHT by addressing key bottlenecks in clinical adoption, including AMF device standardization, long-term MNP biosafety, and scalable nanomanufacturing. This work provides a nano-biomaterials perspective to guide the rational design of next-generation MHT platforms for precision oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.